Ajay K. Singh, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematinics | 46 | 2023 | 281 | 12.430 |
Why?
|
| Anemia | 54 | 2022 | 1499 | 7.970 |
Why?
|
| Erythropoietin | 39 | 2023 | 724 | 7.820 |
Why?
|
| Renal Insufficiency, Chronic | 33 | 2023 | 2195 | 5.090 |
Why?
|
| Hemoglobins | 43 | 2023 | 1532 | 5.060 |
Why?
|
| Renal Dialysis | 34 | 2023 | 1780 | 3.330 |
Why?
|
| Kidney Diseases | 23 | 2019 | 2145 | 2.790 |
Why?
|
| Kidney Failure, Chronic | 27 | 2017 | 2536 | 2.650 |
Why?
|
| Epoetin Alfa | 19 | 2022 | 83 | 2.370 |
Why?
|
| Barbiturates | 5 | 2023 | 114 | 1.880 |
Why?
|
| Glycine | 3 | 2022 | 671 | 1.440 |
Why?
|
| Anemia, Iron-Deficiency | 5 | 2013 | 364 | 1.310 |
Why?
|
| Nephrology | 4 | 2019 | 260 | 0.900 |
Why?
|
| Recombinant Proteins | 22 | 2022 | 6608 | 0.840 |
Why?
|
| Kidney | 10 | 2019 | 7167 | 0.830 |
Why?
|
| Iron | 6 | 2022 | 1773 | 0.730 |
Why?
|
| Ferritins | 6 | 2017 | 590 | 0.700 |
Why?
|
| Bone Diseases, Metabolic | 3 | 2016 | 417 | 0.610 |
Why?
|
| Iron Compounds | 2 | 2008 | 20 | 0.590 |
Why?
|
| Diabetic Nephropathies | 5 | 2019 | 983 | 0.590 |
Why?
|
| Benzhydryl Compounds | 1 | 2023 | 840 | 0.590 |
Why?
|
| Lupus Nephritis | 3 | 2005 | 310 | 0.560 |
Why?
|
| Proteinuria | 4 | 2013 | 657 | 0.470 |
Why?
|
| Certification | 2 | 2019 | 423 | 0.460 |
Why?
|
| Hypertension, Renal | 1 | 2014 | 177 | 0.460 |
Why?
|
| Renal Replacement Therapy | 2 | 2015 | 258 | 0.460 |
Why?
|
| Pathology | 1 | 2016 | 272 | 0.440 |
Why?
|
| Chronic Disease | 16 | 2010 | 9144 | 0.430 |
Why?
|
| Mass Screening | 3 | 2014 | 5238 | 0.430 |
Why?
|
| United States Food and Drug Administration | 3 | 2010 | 1581 | 0.420 |
Why?
|
| Ferric Compounds | 3 | 2008 | 374 | 0.420 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2008 | 30 | 0.400 |
Why?
|
| Humans | 109 | 2023 | 742088 | 0.400 |
Why?
|
| Fanconi Syndrome | 1 | 2011 | 35 | 0.400 |
Why?
|
| Glomerular Filtration Rate | 8 | 2016 | 2167 | 0.400 |
Why?
|
| Ventricular Fibrillation | 1 | 2014 | 538 | 0.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 11695 | 0.390 |
Why?
|
| Saudi Arabia | 5 | 2016 | 209 | 0.380 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 7901 | 0.380 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 425 | 0.370 |
Why?
|
| Occupational Exposure | 1 | 2020 | 1794 | 0.360 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 664 | 0.360 |
Why?
|
| Kidney Tubules | 2 | 2009 | 486 | 0.360 |
Why?
|
| Calcium Compounds | 1 | 2009 | 34 | 0.340 |
Why?
|
| Cardiovascular Diseases | 15 | 2022 | 15108 | 0.340 |
Why?
|
| Biliary Tract Diseases | 1 | 2010 | 160 | 0.340 |
Why?
|
| Middle Aged | 45 | 2022 | 213127 | 0.320 |
Why?
|
| Platelet Activation | 1 | 2012 | 671 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2010 | 9941 | 0.310 |
Why?
|
| Transferrin | 3 | 2008 | 295 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3239 | 0.300 |
Why?
|
| Minerals | 1 | 2009 | 275 | 0.300 |
Why?
|
| Vitamin D | 3 | 2013 | 3211 | 0.300 |
Why?
|
| Male | 56 | 2022 | 349538 | 0.300 |
Why?
|
| Nephritis, Interstitial | 2 | 2008 | 156 | 0.290 |
Why?
|
| Acute Kidney Injury | 3 | 2014 | 1967 | 0.280 |
Why?
|
| Kidney Glomerulus | 1 | 2009 | 697 | 0.280 |
Why?
|
| Female | 55 | 2022 | 379592 | 0.270 |
Why?
|
| India | 3 | 2020 | 2187 | 0.270 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2009 | 359 | 0.260 |
Why?
|
| Prevalence | 10 | 2016 | 15194 | 0.260 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 1541 | 0.260 |
Why?
|
| Evidence-Based Medicine | 4 | 2010 | 3611 | 0.260 |
Why?
|
| Aged | 37 | 2022 | 162944 | 0.260 |
Why?
|
| Societies, Medical | 2 | 2019 | 3740 | 0.260 |
Why?
|
| Treatment Outcome | 23 | 2022 | 62966 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 7 | 2012 | 7276 | 0.250 |
Why?
|
| Phosphates | 1 | 2008 | 786 | 0.250 |
Why?
|
| Erythropoiesis | 2 | 2023 | 705 | 0.240 |
Why?
|
| Cost of Illness | 1 | 2014 | 1852 | 0.240 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 670 | 0.240 |
Why?
|
| Drug Approval | 1 | 2010 | 740 | 0.230 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2283 | 0.230 |
Why?
|
| Heart Arrest | 1 | 2014 | 1469 | 0.230 |
Why?
|
| Risk Factors | 20 | 2020 | 72145 | 0.230 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1331 | 0.230 |
Why?
|
| Injections, Intravenous | 5 | 2008 | 1420 | 0.230 |
Why?
|
| Cytokines | 2 | 2008 | 7317 | 0.230 |
Why?
|
| Early Diagnosis | 3 | 2014 | 1184 | 0.230 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 1768 | 0.220 |
Why?
|
| Cost Savings | 1 | 2008 | 925 | 0.220 |
Why?
|
| Nurse's Role | 1 | 2005 | 209 | 0.220 |
Why?
|
| Kidney Transplantation | 3 | 2009 | 4246 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1661 | 0.220 |
Why?
|
| Ibuprofen | 1 | 2003 | 235 | 0.210 |
Why?
|
| Hyperparathyroidism, Secondary | 2 | 2016 | 126 | 0.210 |
Why?
|
| Glomerulonephritis | 1 | 2004 | 372 | 0.210 |
Why?
|
| Diabetic Angiopathies | 2 | 2019 | 820 | 0.200 |
Why?
|
| Pandemics | 1 | 2022 | 8328 | 0.200 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 774 | 0.200 |
Why?
|
| Liver Diseases | 1 | 2010 | 1252 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2010 | 1155 | 0.200 |
Why?
|
| Granuloma | 1 | 2003 | 315 | 0.200 |
Why?
|
| Blood Platelets | 1 | 2012 | 2506 | 0.200 |
Why?
|
| Heart Failure | 9 | 2019 | 10856 | 0.190 |
Why?
|
| Stroke | 9 | 2021 | 9963 | 0.190 |
Why?
|
| Testis | 1 | 2004 | 800 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2013 | 10943 | 0.180 |
Why?
|
| Endoscopy | 1 | 2010 | 1774 | 0.180 |
Why?
|
| Prognosis | 8 | 2016 | 29010 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2007 | 1359 | 0.180 |
Why?
|
| Tobacco, Smokeless | 1 | 2020 | 129 | 0.180 |
Why?
|
| Albuminuria | 1 | 2023 | 683 | 0.170 |
Why?
|
| Ovary | 1 | 2004 | 981 | 0.170 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2001 | 173 | 0.170 |
Why?
|
| Glucosides | 1 | 2023 | 446 | 0.170 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1640 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2008 | 1575 | 0.170 |
Why?
|
| Fertility | 1 | 2004 | 770 | 0.170 |
Why?
|
| Myocardial Infarction | 5 | 2021 | 11690 | 0.170 |
Why?
|
| Liver Transplantation | 1 | 2010 | 2117 | 0.160 |
Why?
|
| Risk Assessment | 11 | 2019 | 23320 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 657 | 0.160 |
Why?
|
| Research Design | 4 | 2008 | 5979 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 2714 | 0.160 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 2236 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2009 | 2575 | 0.160 |
Why?
|
| Medicare | 4 | 2010 | 6532 | 0.150 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 15056 | 0.150 |
Why?
|
| Adult | 23 | 2023 | 213712 | 0.150 |
Why?
|
| Hypertension | 4 | 2013 | 8455 | 0.150 |
Why?
|
| Infertility | 1 | 2004 | 655 | 0.150 |
Why?
|
| Contrast Media | 2 | 2008 | 5295 | 0.150 |
Why?
|
| Hematocrit | 2 | 2009 | 636 | 0.140 |
Why?
|
| Patients | 1 | 2023 | 892 | 0.140 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4455 | 0.140 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 368 | 0.130 |
Why?
|
| Hospital Mortality | 2 | 2014 | 5310 | 0.130 |
Why?
|
| Biopsy | 5 | 2019 | 6756 | 0.130 |
Why?
|
| Confidence Intervals | 3 | 2012 | 2970 | 0.130 |
Why?
|
| Neoplasms | 2 | 2023 | 21596 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 2337 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2010 | 2275 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2003 | 2205 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 5169 | 0.110 |
Why?
|
| International Cooperation | 2 | 2019 | 1421 | 0.110 |
Why?
|
| Blood Viscosity | 1 | 2013 | 124 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 3123 | 0.110 |
Why?
|
| Age Factors | 4 | 2020 | 18355 | 0.110 |
Why?
|
| Data Collection | 1 | 2022 | 3339 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 4147 | 0.110 |
Why?
|
| Middle East | 1 | 2012 | 219 | 0.100 |
Why?
|
| United States | 10 | 2017 | 69693 | 0.100 |
Why?
|
| Metformin | 1 | 2019 | 829 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2012 | 15530 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 24913 | 0.100 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 683 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 2271 | 0.100 |
Why?
|
| Double-Blind Method | 8 | 2022 | 12017 | 0.100 |
Why?
|
| Comorbidity | 3 | 2013 | 10372 | 0.100 |
Why?
|
| Electric Countershock | 1 | 2014 | 535 | 0.090 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 168 | 0.090 |
Why?
|
| CD40 Ligand | 1 | 2012 | 526 | 0.090 |
Why?
|
| Drug Costs | 2 | 2008 | 1104 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2010 | 4211 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 2099 | 0.090 |
Why?
|
| Program Development | 1 | 2016 | 1314 | 0.090 |
Why?
|
| Drug Monitoring | 2 | 2006 | 956 | 0.090 |
Why?
|
| P-Selectin | 1 | 2012 | 600 | 0.090 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 462 | 0.090 |
Why?
|
| Iron, Dietary | 1 | 2010 | 141 | 0.090 |
Why?
|
| Consumer Product Safety | 1 | 2010 | 122 | 0.090 |
Why?
|
| Cilazapril | 1 | 2008 | 4 | 0.090 |
Why?
|
| Prospective Studies | 7 | 2022 | 53187 | 0.080 |
Why?
|
| Ferrosoferric Oxide | 1 | 2010 | 360 | 0.080 |
Why?
|
| Risk Reduction Behavior | 3 | 2011 | 1123 | 0.080 |
Why?
|
| Survival Rate | 3 | 2014 | 12773 | 0.080 |
Why?
|
| Inflammation | 1 | 2008 | 10578 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2008 | 66 | 0.080 |
Why?
|
| Ergocalciferols | 1 | 2009 | 110 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 63 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 3766 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 362 | 0.080 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2014 | 979 | 0.080 |
Why?
|
| Sclerosis | 1 | 2008 | 210 | 0.080 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 2645 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2013 | 2295 | 0.080 |
Why?
|
| Drug Labeling | 1 | 2010 | 231 | 0.080 |
Why?
|
| Publication Bias | 1 | 2008 | 161 | 0.080 |
Why?
|
| Phosphorus | 1 | 2009 | 338 | 0.080 |
Why?
|
| Cardiac Output | 1 | 2010 | 853 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 3957 | 0.080 |
Why?
|
| Calcitriol | 1 | 2009 | 298 | 0.080 |
Why?
|
| Logistic Models | 2 | 2020 | 13403 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3510 | 0.070 |
Why?
|
| Organotechnetium Compounds | 1 | 2007 | 137 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 379 | 0.070 |
Why?
|
| Age Distribution | 1 | 2013 | 2900 | 0.070 |
Why?
|
| Polycythemia | 1 | 2008 | 126 | 0.070 |
Why?
|
| Models, Biological | 1 | 2003 | 9581 | 0.070 |
Why?
|
| Biological Availability | 1 | 2007 | 396 | 0.070 |
Why?
|
| Disease Progression | 4 | 2017 | 13256 | 0.070 |
Why?
|
| Patient Selection | 2 | 2010 | 4214 | 0.070 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2008 | 186 | 0.070 |
Why?
|
| Half-Life | 1 | 2007 | 658 | 0.070 |
Why?
|
| Leuprolide | 1 | 2008 | 303 | 0.070 |
Why?
|
| Awareness | 1 | 2010 | 639 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 974 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 3915 | 0.070 |
Why?
|
| Retrospective Studies | 8 | 2016 | 77098 | 0.070 |
Why?
|
| Radiopharmaceuticals | 2 | 2007 | 2658 | 0.060 |
Why?
|
| Histology | 1 | 2004 | 16 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2008 | 689 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2009 | 10248 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 314 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 277 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2008 | 545 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2007 | 421 | 0.060 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 269 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 1440 | 0.060 |
Why?
|
| Iothalamic Acid | 1 | 2003 | 18 | 0.060 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2003 | 68 | 0.060 |
Why?
|
| Prednisone | 1 | 2008 | 1567 | 0.060 |
Why?
|
| Nephrosis | 1 | 2003 | 45 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 425 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2012 | 6452 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 12958 | 0.060 |
Why?
|
| Ovum | 1 | 2004 | 189 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2007 | 416 | 0.060 |
Why?
|
| Adolescent | 6 | 2016 | 85649 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2763 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 6534 | 0.060 |
Why?
|
| Curriculum | 1 | 2016 | 3589 | 0.050 |
Why?
|
| Probability | 1 | 2008 | 2502 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2008 | 728 | 0.050 |
Why?
|
| Nephritis | 1 | 2003 | 158 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 725 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 1676 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2008 | 1049 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 802 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2004 | 477 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2014 | 4567 | 0.050 |
Why?
|
| Sex Factors | 2 | 2013 | 10392 | 0.050 |
Why?
|
| Quality of Life | 4 | 2023 | 12730 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2012 | 2616 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 57683 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2014 | 40450 | 0.050 |
Why?
|
| Sirolimus | 1 | 2009 | 1562 | 0.050 |
Why?
|
| Reference Values | 2 | 2013 | 4982 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 1517 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 6483 | 0.050 |
Why?
|
| Algorithms | 3 | 2012 | 13853 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2001 | 67 | 0.050 |
Why?
|
| Morbidity | 1 | 2006 | 1767 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2008 | 859 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2010 | 5062 | 0.050 |
Why?
|
| Calcium | 2 | 2016 | 5753 | 0.050 |
Why?
|
| Health Care Reform | 1 | 2010 | 1261 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2008 | 1166 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2014 | 6440 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2010 | 8297 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 1873 | 0.050 |
Why?
|
| Young Adult | 4 | 2017 | 56350 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2009 | 2452 | 0.050 |
Why?
|
| Spermatozoa | 1 | 2004 | 625 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 1030 | 0.040 |
Why?
|
| Hospitalization | 3 | 2009 | 10232 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1509 | 0.040 |
Why?
|
| Thrombosis | 2 | 2006 | 2966 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 4771 | 0.040 |
Why?
|
| Risk | 2 | 2010 | 9679 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 1847 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2004 | 664 | 0.040 |
Why?
|
| Calcinosis | 1 | 2008 | 1497 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2005 | 921 | 0.040 |
Why?
|
| Oocytes | 1 | 2004 | 1186 | 0.040 |
Why?
|
| Nucleosomes | 1 | 2002 | 493 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2013 | 4030 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2008 | 3199 | 0.040 |
Why?
|
| Causality | 1 | 2005 | 1265 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 12242 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2016 | 40955 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 1692 | 0.040 |
Why?
|
| Length of Stay | 2 | 2014 | 6294 | 0.040 |
Why?
|
| Child | 4 | 2016 | 77478 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2007 | 2066 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11363 | 0.040 |
Why?
|
| Acute Disease | 1 | 2008 | 7141 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2017 | 145 | 0.040 |
Why?
|
| Incidence | 2 | 2012 | 20928 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 1431 | 0.040 |
Why?
|
| Developing Countries | 1 | 2009 | 2789 | 0.040 |
Why?
|
| Cause of Death | 2 | 2019 | 3571 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4414 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2009 | 9846 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 39004 | 0.030 |
Why?
|
| Inpatients | 1 | 2008 | 2495 | 0.030 |
Why?
|
| Massachusetts | 1 | 2009 | 8662 | 0.030 |
Why?
|
| Education, Distance | 1 | 2019 | 251 | 0.030 |
Why?
|
| Medicaid | 1 | 2008 | 2716 | 0.030 |
Why?
|
| Oliguria | 1 | 2014 | 21 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2008 | 4393 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2010 | 4681 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2007 | 1904 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2011 | 21719 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 20086 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2002 | 2036 | 0.030 |
Why?
|
| Creatinine | 2 | 2009 | 1916 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 12344 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 40054 | 0.030 |
Why?
|
| Hemoglobinometry | 1 | 2012 | 35 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2013 | 321 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7153 | 0.030 |
Why?
|
| Diuretics | 1 | 2014 | 591 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 5724 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 14720 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 939 | 0.020 |
Why?
|
| Thailand | 1 | 2009 | 296 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2016 | 1801 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 1813 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13655 | 0.020 |
Why?
|
| Mortality | 1 | 2019 | 2857 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2450 | 0.020 |
Why?
|
| Animals | 2 | 2009 | 168561 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9715 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 2354 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2007 | 981 | 0.020 |
Why?
|
| Executive Function | 1 | 2013 | 1362 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 2566 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2006 | 579 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6365 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2008 | 1458 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 2007 | 402 | 0.010 |
Why?
|
| Memory | 1 | 2013 | 2163 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 2027 | 0.010 |
Why?
|
| Linear Models | 1 | 2013 | 5948 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1650 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2217 | 0.010 |
Why?
|
| Sepsis | 1 | 2014 | 2589 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1679 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 6974 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9305 | 0.010 |
Why?
|
| Disease Management | 1 | 2009 | 2450 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2006 | 2706 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2007 | 2346 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 13921 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 35070 | 0.010 |
Why?
|